公开(公告)号：US20210393695A1

公开(公告)日：2021-12-23

申请号：US17369831

申请日：2021-07-07

申请人： Fate Therapeutics, Inc.

发明人： Jonathan Rosen ,  Betsy Rezner ,  Bahram Valamehr ,  Ryan Bjordahl ,  Eigen Peralta

IPC分类号： A61K35/17 ,  C12N5/0783 ,  G01N33/50 ,  A61K31/713 ,  A61K31/7084 ,  A61K31/7105 ,  A61K45/06 ,  A61K31/506 ,  A61P31/00 ,  A61P37/06 ,  A61P35/00 ,  A61K31/436

摘要： Compounds that either produced a higher proportion or greater absolute number of phenotypically identified nave, stem cell memory, central memory T cells, adaptive NK cells, and type I NKT cells are identified. Compositions and methods for modulating immune cells including T, NK, and NKT cells for adoptive cell therapies with improved efficacy are provided.

公开(公告)号：US11072781B2

公开(公告)日：2021-07-27

申请号：US16379668

申请日：2019-04-09

申请人： Fate Therapeutics, Inc.

发明人： Bahram Valamehr ,  Ramzey Abujarour ,  Tom Tong Lee ,  Weijie Lan ,  Raedun Clarke ,  Ryan Bjordahl

IPC分类号： C12N5/00 ,  C12N5/074 ,  C12N15/90 ,  C12N5/0783 ,  A61P35/02 ,  C07K16/28 ,  A61P35/00 ,  C12N5/078 ,  C12N15/85 ,  A61K35/17 ,  C07K14/705 ,  C07K14/725 ,  C12N9/22 ,  C12N15/11 ,  C12N15/113 ,  A61K35/12

摘要： Provided are methods and compositions for obtaining genome-engineered iPSCs, and derivative cells with stable and functional genome editing at selected sites. Also provided are cell populations or clonal cell lines derived from genome-engineered iPSCs, which comprise targeted integration of one or more exogenous polynucleotides, and/or in/dels in one or more selected endogenous genes.

公开(公告)号：US10954529B2

公开(公告)日：2021-03-23

申请号：US16007928

申请日：2018-06-13

申请人： Fate Therapeutics, Inc.

发明人： Peter Flynn ,  Bahram Valamehr

IPC分类号： C12N5/00 ,  C12N15/85 ,  A61K35/545 ,  A61K35/51 ,  A61K35/12

摘要： The invention provides compositions and methods for reprogramming minimal volumes of mononuclear cells. In particular aspects, the invention provides methods and compositions for reprogramming minimal volumes of umbilical cord blood obtained from cord blood segments from cryopreserved cord blood segments.

公开(公告)号：US10858628B2

公开(公告)日：2020-12-08

申请号：US15773519

申请日：2016-07-26

申请人： Fate Therapeutics, Inc.

发明人： Bahram Valamehr ,  Raedun Clarke ,  Ryan Bjordahl

IPC分类号： C12N5/0789 ,  A61K35/28 ,  G01N33/50 ,  A61K39/00 ,  A61K35/545

摘要： The invention provides culture platforms, cell media, and methods of differentiating pluripotent cells into hematopoietic cells. The invention further provides pluripotent stem cell-derived hematopoietic cells generated using the culture platforms and methods disclosed herein, which enable feed-free, monolayer culturing and in the absence of EB formation. Specifically, pluripotent stem cell-derived hematopoietic cell of this invention include, and not limited to, iHSC, definitive hemogenic endothelium, hematopoietic multipotent progenitors, T cell progenitors, NK cell progenitors, T cells, NK cells, NKT cells and B cells.

公开(公告)号：US20180112180A1

公开(公告)日：2018-04-26

申请号：US15546255

申请日：2016-01-26

申请人： Fate Therapeutics, Inc.

发明人： David Robbins ,  Betsy Rezner ,  Leah Mitchell ,  Lisa Guerrettaz ,  Philippe Alessandro Parone ,  Robert Steven Tacke ,  Kevin Lai ,  Bahram Valamehr

IPC分类号： C12N5/0789 ,  C07K14/705 ,  C12N9/02 ,  A61K35/28 ,  A61K38/17 ,  A61K38/44 ,  A61P37/00 ,  A61P29/00

CPC分类号： C12N5/0647 ,  A61K35/28 ,  A61K38/1774 ,  A61K38/44 ,  A61K2035/124 ,  A61K2039/577 ,  A61P29/00 ,  A61P37/00 ,  C07K14/555 ,  C07K14/70532 ,  C07K14/70596 ,  C12N5/0636 ,  C12N9/0069 ,  C12N2501/02 ,  C12N2501/056 ,  C12N2501/24 ,  C12N2501/48 ,  C12N2501/51 ,  C12N2501/599 ,  C12N2501/71 ,  C12N2501/999 ,  C12N2502/1171 ,  C12Y113/11052

摘要： The present invention is directed to compositions and methods to increase the expression of PD-L1 and/or IDO-1 in a population of cells, the modulated cells expressing increased PD-L1 and/or IDO-1, and methods related to the immunosuppressive effects obtained by cells expressing increased PD-L1 and/or IDO-1.

公开(公告)号：US11352607B2

公开(公告)日：2022-06-07

申请号：US16656484

申请日：2019-10-17

申请人： Fate Therapeutics, Inc.

发明人： Bahram Valamehr ,  Ramzey Abujarour ,  Tom Tong Lee ,  Weijie Lan ,  Raedun Clarke ,  Ryan Bjordahl

IPC分类号： C12N5/074 ,  C12N15/90 ,  C12N5/0783 ,  A61P35/02 ,  C07K16/28 ,  A61P35/00 ,  C12N5/078 ,  C12N15/85 ,  A61K35/17 ,  C07K14/705 ,  C07K14/725 ,  C12N9/22 ,  C12N15/11 ,  C12N15/113 ,  A61K35/12

摘要： Provided are methods and compositions for obtaining genome-engineered iPSCs, and derivative cells with stable and functional genome editing at selected sites. Also provided are cell populations or clonal cell lines derived from genome-engineered iPSCs, which comprise targeted integration of one or more exogenous polynucleotides, and/or in/dels in one or more selected endogenous genes.

公开(公告)号：US11162075B2

公开(公告)日：2021-11-02

申请号：US17062475

申请日：2020-10-02

申请人： FATE THERAPEUTICS, INC.

发明人： Bahram Valamehr ,  Raedun Clarke ,  Ryan Bjordahl

IPC分类号： C12N5/0789 ,  A61K35/28 ,  G01N33/50 ,  A61K39/00 ,  A61K35/545

摘要： The invention provides culture platforms, cell media, and methods of differentiating pluripotent cells into hematopoietic cells. The invention further provides pluripotent stem cell-derived hematopoietic cells generated using the culture platforms and methods disclosed herein, which enable feed-free, monolayer culturing and in the absence of EB formation. Specifically, pluripotent stem cell-derived hematopoietic cell of this invention include, and not limited to, iHSC, definitive hemogenic endothelium, hematopoietic multipotent progenitors, T cell progenitors, NK cell progenitors, T cells, NK cells, NKT cells and B cells.

公开(公告)号：US20200172870A1

公开(公告)日：2020-06-04

申请号：US16701013

申请日：2019-12-02

申请人： Fate Therapeutics, Inc.

发明人： David Robbins ,  Betsy Rezner ,  Leah Mitchell ,  Lisa Guerrettaz ,  Philippe Alessandro Parone ,  Robert Steven Tacke ,  Kevin Lai ,  Bahram Valamehr

IPC分类号： C12N5/0789 ,  C07K14/705 ,  C12N5/0783 ,  C07K14/555 ,  A61K38/44 ,  A61K38/17 ,  A61P29/00 ,  A61P37/00 ,  A61K35/28 ,  C12N9/02

摘要： The present invention is directed to compositions and methods to increase the expression of PD-L1 and/or IDO-1 in a population of cells, the modulated cells expressing increased PD-L1 and/or IDO-1, and methods related to the immunosuppressive effects obtained by cells expressing increased PD-L1 and/or IDO-1.

公开(公告)号：US10023879B2

公开(公告)日：2018-07-17

申请号：US14731403

申请日：2015-06-04

申请人： FATE THERAPEUTICS, INC.

发明人： Peter Flynn ,  Bahram Valamehr

IPC分类号： C12N5/00 ,  C12N15/85 ,  A61K35/545 ,  A61K35/51 ,  A61K35/12

摘要： The invention provides compositions and methods for reprogramming minimal volumes of mononuclear cells. In particular aspects, the invention provides methods and compositions for reprogramming minimal volumes of umbilical cord blood obtained from cord blood segments from cryopreserved cord blood segments.

公开(公告)号：US20180155717A1

公开(公告)日：2018-06-07

申请号：US15818649

申请日：2017-11-20

申请人： Fate Therapeutics, Inc.

发明人： Bahram Valamehr ,  Ramzey Abujarour ,  Tom Tong Lee ,  Weijie Lan ,  Raedun Clarke ,  Ryan Bjordahl

IPC分类号： C12N15/11 ,  A61K35/17 ,  C12N5/074 ,  C07K14/705 ,  C07K14/725 ,  C12N9/22 ,  C12N15/85

CPC分类号： C12N15/11 ,  A61K35/17 ,  C07K14/70503 ,  C07K14/7051 ,  C12N5/0696 ,  C12N9/22 ,  C12N15/1138 ,  C12N15/85 ,  C12N15/90 ,  C12N15/907 ,  C12N2310/20 ,  C12N2501/25 ,  C12N2501/505 ,  C12N2501/51 ,  C12N2501/515 ,  C12N2501/599 ,  C12N2501/998 ,  C12N2510/00 ,  C12N2800/80 ,  C12N2830/00

摘要： Provided are methods and compositions for obtaining genome-engineered iPSCs, and derivative cells with stable and functional genome editing at selected sites. Also provided are cell populations or clonal cell lines derived from genome-engineered iPSCs, which comprise targeted integration of one or more exogenous polynucleotides, and/or in/dels in one or more selected endogenous genes.